Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002230123 | SCV000551242 | pathogenic | Hereditary nonpolyposis colorectal neoplasms | 2023-05-02 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 410503). This variant has not been reported in the literature in individuals affected with MSH6-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Lys334Argfs*4) in the MSH6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH6 are known to be pathogenic (PMID: 18269114, 24362816). |
Gene |
RCV000522846 | SCV000618302 | pathogenic | not provided | 2017-02-27 | criteria provided, single submitter | clinical testing | This deletion of one nucleotide in MSH6 is denoted c.999delC at the cDNA level and p.Lys334ArgfsX4 (K334RfsX4) at the protein level. The normal sequence, with the base that is deleted in brackets, is AAAC[delC]AAGA. The deletion causes a frameshift which changes a Lysine to an Arginine at codon 334, and creates a premature stop codon at position 4 of the new reading frame. Although this variant has not, to our knowledge, been reported in the literature, it is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. We consider this variant to be pathogenic. |
Myriad Genetics, |
RCV003449151 | SCV004185634 | pathogenic | Lynch syndrome 5 | 2023-08-11 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. |
Baylor Genetics | RCV004568056 | SCV005054861 | likely pathogenic | Endometrial carcinoma | 2024-03-09 | criteria provided, single submitter | clinical testing |